Figure 2.
Effects of voxelotor on cerebral hemodynamic markers. (A-C) Box plots of OEF, CBFi (1 × 10−7 cm2/s), and CBV (mL per 100 g) from pretreatment (black) to 4, 8, and 12 weeks after treatment (red). ∗P < .05; ∗∗P < .01; and ∗∗∗P < .001 compared with pretreatment levels using 2-sided paired Wilcoxon signed-rank test. (D-F) Box plots of relative percent changes from pretreatment levels of oxygen extraction fraction (rOEF), cerebral blood flow (rCBFi), and cerebral blood volume (rCBV) from pretreatment. The horizontal gray dotted line at 0 denotes no change from pretreatment levels. For each box plot, the central line denotes the median, and the bottom and top edges of the box indicate the 25th and 75th percentiles, respectively. The whiskers extend to the most extreme data points not considered outliers. Individual connected gray dots represent each pretreatment and posttreatment matched pair for the 8 patients.

Effects of voxelotor on cerebral hemodynamic markers. (A-C) Box plots of OEF, CBFi (1 × 10−7 cm2/s), and CBV (mL per 100 g) from pretreatment (black) to 4, 8, and 12 weeks after treatment (red). ∗P < .05; ∗∗P < .01; and ∗∗∗P < .001 compared with pretreatment levels using 2-sided paired Wilcoxon signed-rank test. (D-F) Box plots of relative percent changes from pretreatment levels of oxygen extraction fraction (rOEF), cerebral blood flow (rCBFi), and cerebral blood volume (rCBV) from pretreatment. The horizontal gray dotted line at 0 denotes no change from pretreatment levels. For each box plot, the central line denotes the median, and the bottom and top edges of the box indicate the 25th and 75th percentiles, respectively. The whiskers extend to the most extreme data points not considered outliers. Individual connected gray dots represent each pretreatment and posttreatment matched pair for the 8 patients.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal